<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04017455</url>
  </required_header>
  <id_info>
    <org_study_id>N18TRZ</org_study_id>
    <nct_id>NCT04017455</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN)</brief_title>
  <acronym>TARZAN</acronym>
  <official_title>Neoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, patients with resectable rectal cancer will receive radiotherapy, followed by
      neoadjuvant bevacizumab and atezolizumab
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      38 patients with resectable rectal cancer will be enrolled. All patients will be treated with
      radiotherapy followed by bevacizumab and atezolizumab.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2019</start_date>
  <completion_date type="Anticipated">August 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>single group, open label</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clinical complete and near-complete response rate</measure>
    <time_frame>12 weeks post-radiotherapy</time_frame>
    <description>response rate will be assessed by MRI and endoscopy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of adverse events following treatment (safety)</measure>
    <time_frame>untill 100 days after last patient last study drug</time_frame>
    <description>adverse events will be assessed (according tot CTC-AE v5) during treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>local recurrence rate at 1 year follow-up</measure>
    <time_frame>1 year post-radiotherapy</time_frame>
    <description>recurrence will be assessed by MRI and CT scans</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>bevacizumab and atezolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 cycle of bevacizumab monotherapy, followed by 2 cycles of bevacizumab combined with atezolizumab, followed by 1 cycle of atezolizumab monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>3 cycles of atezolizumab 840 mg</description>
    <arm_group_label>bevacizumab and atezolizumab</arm_group_label>
    <other_name>MPDL3280A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>3 cycles of bevacizumab 5mg/kg</description>
    <arm_group_label>bevacizumab and atezolizumab</arm_group_label>
    <other_name>HCA 185 ,Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  signed informed consent

          -  patients age 18 years and older

          -  histologically confirmed adenocarcinoma of the rectum

          -  intermediate risk rectal cancer or low risk distal rectal cancer

        Exclusion Criteria:

          -  evidence of metastatic disease

          -  prior radiation therapy for disease under study

          -  prior treatment with CD137 agonists or immune checkpoint blockade therapies

          -  current or recent use of acetylsalicylic acid

          -  history of clinically significant cardiac or pulmonary dysfunction pregnancy or
             breastfeeding

          -  significant auto-immune disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myriam Chalabi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Antoni van Leeuwenhoek</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elvira Nuijten, MSc</last_name>
    <phone>+3120512</phone>
    <phone_ext>2220</phone_ext>
    <email>e.nuijten@nki.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Antoni van Leeuwenhoek</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1066CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elvira Nuijten</last_name>
      <phone>+3120512</phone>
      <phone_ext>2220</phone_ext>
      <email>e.nuijten@nki.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 10, 2019</study_first_submitted>
  <study_first_submitted_qc>July 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2019</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>short term immunotherapy</keyword>
  <keyword>atezolizumab</keyword>
  <keyword>bevacizumab</keyword>
  <keyword>radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

